Ginkgo Bioworks IPO
Ginkgo Bioworks is a synthetic biology company that uses engineered microorganisms to produce chemicals, materials, and other products. Investors are interested in the company's platform approach to biotechnology and its potential to revolutionize manufacturing across multiple industries.
What We Know
Ginkgo Bioworks went public in September 2021 through a SPAC merger with Soaring Eagle Acquisition Corp, valuing the company at approximately $2.5 billion. The stock began trading on the NYSE under the ticker symbol 'DNA'. Since going public, the company's stock performance has been volatile, reflecting broader market sentiment toward growth-stage biotech companies and SPACs. Ginkgo continues to expand its synthetic biology platform and partnerships across various industries including pharmaceuticals, agriculture, and industrial biotechnology.
Frequently Asked Questions
Has Ginkgo Bioworks had an IPO?
Yes, Ginkgo Bioworks completed its IPO in September 2021 through a SPAC merger. The company now trades publicly on the NYSE under the ticker symbol 'DNA'.
When is the Ginkgo Bioworks IPO date?
Ginkgo Bioworks already went public in September 2021, so there is no upcoming IPO date. The company completed its public listing through a SPAC transaction.
How can I buy Ginkgo Bioworks stock?
You can buy Ginkgo Bioworks stock through any major brokerage since it trades publicly on the NYSE under ticker 'DNA'. The stock is available for purchase during regular market hours through traditional investment accounts.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts